Company: IMRX
Filing Date: 2025-01-07
Form Type: 8-K
Source: 0001790340-25-000012
Chunk: 1

Company: Immuneering Corp
Filing Date: 2025-01-07
Form: 8-K
Item: Item 8.01
Chunk 1
---
 2a Arm Evaluating IMM-1-104 with Modified FOLFIRINOX (mFFX) in First-Line Pancreatic Cancer Patients

The Company announced that, as of December 5, 2024, of the four evaluable patients in the ongoing Phase 2a arm evaluating IMM-1-104 with FFX in first-line pancreatic cancer, all four patients achieved target tumor shrinkage and disease control, including one patient that achieved a partial response with a one-hundred percent (100%) target lesion reduction, in each case as measured by RECIST. The Company also announced that, as of December 5, 2024, IMM-1-104 in combination with mFFX was observed to be generally well tolerated.

Initial Interim Data from Ongoing Phase 2a Arm Evaluating IMM-1-104 Monotherapy in Second-Line Pancreatic Cancer Patients

The Company announced that, as of December 5, 2024, of the twenty-one evaluable patients in the ongoing Phase 2a arm evaluating IMM-1-104 monotherapy in second-line pancreatic cancer, eleven patients achieved disease control, including one patient that achieved a partial response with a sixty-seven percent (67%) target lesion reduction, in each case as measured by RECIST. The patient that achieved the forementioned partial response, and eight of the patients that achieved stable disease, remained on treatment. The Company also announced that, as of December 5, 2024, IMM-1-104 monotherapy was observed to be very well tolerated. As of December 5, 2024, treatment-related adverse events (TRAEs) observed in ten-percent (10%) or greater of evaluable patients dosed with IMM-1-104 at 320mg (n=21) were mostly Grade 1 events, with some Grade 2 events observed including for: Rash (1 patient or 5%), Diarrhea (2 patients or 10%), Fatigue (1 patient or 5%) and Blurred Vision (1 patient or 5%); no Grade 3, Grade 4 or Grade 5 TRAEs were observed in this subset of the patient population.

Initial Interim PK, PD and Safety Data from Phase 1 Portion of the Company’s Ongoing Phase 1/2a Trial Evaluating IMM-6-415 Monotherapy in Patients with Advanced Solid Tumors Harboring RAF or RAS Mutations

The Company announced that, as of December 23